Search

Author/Creator Nash, Peter

1. 171 Secukinumab provides sustained PASDAS related low disease activity in psoriatic arthritis: two year results from the FUTURE 2 study. (25th April 2018)

Authors:
Coates, Laura C; Gladman, Dafna; Nash, Peter; Fitzgerald, Oliver; Kavanaugh, Arthur; Rasouliyan, Lawrence; Pricop, Luminita; Ding, Kevin; Gaillez, Corine
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. 175 Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal Phase III clinical trial data. (25th April 2018)

Authors:
Kaul, Arvind; Strand, Vibeke; McInnes, Iain; Mease, Philip; Choy, Ernest; Nash, Peter; Thom, Howard; Kalyvas, Chrysostomos; Gandhi, Kunal; Pricop, Luminita; Jugl, Steffen
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 185 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses. (25th April 2018)

Authors:
McInnes, Iain; Mease, Philip; Reich, Kristian; Nash, Peter; Andersson, Mats; Abrams, Ken; Pricop, Luminita; Fox, Todd
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. 2018 update of the APLAR recommendations for treatment of rheumatoid arthritis. (27th February 2019)

Authors:
Lau, Chak Sing; Chia, Faith; Dans, Leonila; Harrison, Andrew; Hsieh, Tsu Yi; Jain, Rahul; Jung, Seung Min; Kishimoto, Mitsumasa; Kumar, Ashok; Leong, Khai Pang; Li, Zhanguo; Lichauco, Juan Javier; Louthrenoo, Worawit; Luo, Shue Fen; Mu, Rong; Nash, Peter; Ng, Chin Teck; Suryana, Bagus; Wijaya, Li...
Journal:
International journal of rheumatic diseases
Issue:
Volume 22:Number 3(2019)
Page Start:
357
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

6. 233 Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib. (25th April 2018)

Authors:
Smolen, Josef S; Dougados, Maxime; Takeuchi, Tsutomu; Genovese, Mark C; Haraoui, Boulos; Klar, Rena; Kavanaugh, Arthur; Alonso, Ricardo B; Dudler, Jean; Taylor, Peter C; Nash, Peter; Zerbini, Cristiano A; Durez, Patrick; Pum, Georg; Arthanari, Subhashini; De Leonardis, Francesco; van Vollenhoven,...
Journal:
Rheumatology
Issue:
Volume 57(2018)Supplement 3
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial. Issue 1 (28th September 2019)

Authors:
Mease, Philip J; Smolen, Josef S; Behrens, Frank; Nash, Peter; Liu Leage, Soyi; Li, Lingnan; Tahir, Hasan; Gooderham, Melinda; Krishnan, Eswar; Liu-Seifert, Hong; Emery, Paul; Pillai, Sreekumar G; Helliwell, Philip S
Journal:
Annals of the rheumatic diseases
Issue:
Volume 79:Issue 1(2020)
Page Start:
123
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. A patient‐centered knowledge translation tool for treat‐to‐target strategy in rheumatoid arthritis: Patient and rheumatologist perspectives. (19th January 2021)

Authors:
Benham, Helen; Chiu, Hedva; Tesiram, Joanne; Mehdi, Ahmed; Landsberg, Peter; Grosman, Sergei; Harrison, Andrew; Nash, Peter; Thomas, Ranjeny; Langbecker, Danette; Van Driel, Mieke
Journal:
International journal of rheumatic diseases
Issue:
Volume 24:Number 3(2021)
Page Start:
355
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗